mTOR pathway in colorectal cancer: an update.
mTOR pathway in colorectal cancer: an update.
复制标题
DOI：
10.18632/oncotarget.1548
复制
发表时间：
2014-01-15
期刊：
影响因子：
--
通讯作者：
Lagasse E
中科院分区：
文献类型：
--
作者：
Francipane MG;Lagasse E
雷帕霉素的哺乳动物靶点(MTOR)已成为药物开发的潜在靶点，特别是由于它在癌症生物学中扮演着如此关键的角色。此外，下一代mTOR抑制剂已经上市，标志着基于mTOR的治疗进入了一个令人兴奋的新阶段。然而，对它们的治疗效果的裁决仍不清楚。本文综述了磷脂酰肌醇-3-激酶(PI3K)/Akt/mTOR信号通路作为维持肿瘤生长和转移的主要机制之一、mTOR抑制剂的最新研究进展以及结直肠癌(CRC)中mTOR激活/抑制的研究现状。我们还将讨论我们最近在一组结肠癌干细胞(CSCs)中对不同mTOR抑制剂的比较研究，以及目前使用激酶抑制剂实现个体化药物治疗的主要挑战。
The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug development, particularly due to the fact that it plays such a crucial role in cancer biology. In addition, next-generation mTOR inhibitors have become available, marking an exciting new phase in mTOR-based therapy. However, the verdict on their therapeutic efectiveness remains unclear. Here we review phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR signaling as one of the primary mechanisms for sustaining tumor outgrowth and metastasis, recent advances in the development of mTOR inhibitors, and current studies addressing mTOR activation/inhibition in colorectal cancer (CRC). We will also discuss our recent comparative study of diferent mTOR inhibitors in a population of colon cancer stem cells (CSCs), and current major challenges for achieving individualized drug therapy using kinase inhibitors.